Synchron as Neuralink's Main Competitor

Synchron is the clearest direct check on Neuralink because it is solving the same first job, letting people with severe paralysis control phones and computers, but with a procedure that fits existing catheter labs instead of a neurosurgery stack. That makes the real competition less about science fiction bandwidth, and more about which product can get into more hospitals, more clinicians, and more patients with acceptable performance first.

• Synchron’s Stentrode is delivered through the jugular vein into a vessel near the motor cortex, then linked to a chest implant and wireless device. In practice, that means a roughly two hour vascular procedure, short hospital stay, and use of interventional radiology workflows that already exist at scale.
  2 sacra 4 synchron
• Neuralink’s advantage is signal density and control fidelity. Its system uses brain inserted threads, custom chips, and a surgical robot, which has enabled stronger cursor control, but also requires opening the skull and managing long term implant reliability inside brain tissue.
  1 sacra 3 neuralink
• The market is already sorting around this tradeoff. Apple added a BCI protocol to Switch Control for users with severe mobility disabilities, and Synchron became the first implementation partner, which shows how a lower bandwidth device can still win if it plugs into mainstream software and works reliably enough for daily use.
  2 sacra 5 apple 6 apple

Going forward, the category is likely to split into two lanes. Endovascular systems should move faster in clinical adoption because they match existing hospital infrastructure, while open brain systems push toward higher performance applications. The company that best combines enough control, easiest implantation, and deepest device integration will set the commercial pace for early BCI adoption.